Medmix Ag · SIX:MEDX
Medmix — January 2023 equities conferences
22 slides from Medmix's conference presentation, January 2023
Slide 1: medmix
medmix CONFIDENTIAL
Slide 2: Investor Presentation January 2023
Investor Presentation January 2023 medmix CONFIDENTIAL
Slide 3: The safe harbor statement under the US private securities litigation reform act 1995
The safe harbor statement under the US private securities litigation reform act 1995 This presentation may contain forward-looking statements, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, containing risks and
Slide 4: Overview
Overview medmix CONFIDENTIAL
Slide 5: Medmix in 2021 and global footprint
Medmix in 2021 Global footprint 15 * ~2,000 employees Production, logistics and distribution sites 25% >2.5bn CHF 457m revenue adj. EBITDA margin Products per year ~900 active patents 5 Note: * as at 31 December 2022 medmix CONFIDENTIAL
Slide 6: Innovative, high-precision delivery devices serving attractive markets
Innovative, high-precision delivery devices serving attractive markets Healthcare Consumer and Industrial Drug Dental Surgery Industry Beauty Delivery Gold standard in Award winning, Pioneer in bone Leader in industrial mixing Leading microbrush dental mixing device proprietary injection cement mixi
Slide 7: Attractive fundamental macro trends
Attractive fundamental macro trends Market growth forecast post Macro trends recovery to 2025E (CAGR)1,2 Main segment trends • Aging population Growing Dental middle-class market 2% • Emerging markets shift away from hand- to device-mixing • Trend to unit-dose to avoid cross-contamination Drug • Tre
Slide 8: Sustainability at medmix
Sustainability at medmix Manufacturing sites • Secured organization carbon footprint verifications for all sites from TÜV NORD CERT, an external provider of certifications and assessments • Haag site upgraded to a gold rating from Ecovadis, an external provider of business sustainability ratings and
Slide 9: Key events
Key events New US healthcare facility • In April 2022, medmix entered into a leasing of an industrial building near Atlanta, Georgia, USA. From this facility, medmix Drug Delivery will provide pen injectors and autoinjectors, as well as pharma packaging services. This site will be equipped with a st
Slide 10: M&A update
M&A update Spain • In October 2022 medmix closed its acquisition of the plastics business of Universal de Suministros, a Spanish manufacturer of cartridges, mixers & accessories for construction & industrial adhesives related markets • medmix expects to invest CHF 10 million to ramp up production at
Slide 11: H1 22
H1 22 medmix CONFIDENTIAL
Slide 12: H1 22 update
H1 22 update • H1 22 revenue up 9.8% YOY (10.2% FX adjusted) • Record production and revenue in H1 2022 despite geopolitical headwinds • Strong momentum in Healthcare strategy across all market Segments: ➢ Launch of PiccoJect™ innovative autoinjector platform ➢ On track for our new US Healthcare pro
Slide 13: H1 2022 Revenue and H2 2022 trends
H1 2022 Revenue and H2 2022 trends Healthcare Consumer and Industrial Drug Dental Surgery Industry Beauty Delivery 71.3 +15.7% 23.8 +16.8% 6.7 +16.2% 79.2 -0.5% 69.5 +15.8% Strong performance Higher demand from Growth in tissue bank Continued demand from Volume driven increase especially in the US a
Slide 14: Healthcare
Healthcare Growth in all Healthcare market Segments Key figures Revenue split In CHF millions H1 2022 H1 2021 YOY adj.1 Surgery Revenue 101.9 87.9 +16.0% +16.0% 7% Business Area Gross Profit 63.8 54.3 +17.3% Business Area Gross Profit margin % 62.6% 61.9% +0.7pts Drug Delivery 23% H1 2022 Highlights
Slide 15: Healthcare – Drug Delivery
Healthcare – Drug Delivery Outlook 2025 Expected Drug Delivery revenue development Secured new products by API clinical stage CHF 100m Expected 2025 revenue split by indication Secured: US biotech announced in H1 21 at 100% plan, others at 75% plan Pipeline: at 50% plan (~20% of 2025 revenue) 15 med
Slide 16: Consumer & Industrial
Consumer & Industrial Robust performance despite Polish sanctions Key figures Revenue split In CHF millions H1 2022 H1 2021 YOY adj.1 Revenue 148.7 140.5 +5.9% +6.7% Beauty Industry Business Area Gross Profit 56.1 57.3 (2.0)% 47% 53% Business Area Gross Profit margin % 37.7% 40.8% (3.1)pts H1 2022 H
Slide 17: Financials
Financials medmix CONFIDENTIAL
Slide 18: H1 2022 Results
H1 2022 Results medmix continues on its growth path in a challenging environment CHF millions Key figures Highlights 1H’22 1H’21 YOY adj.1 • Revenue growth at the top of our full year Revenue 250.6 228.3 9.8% 10.2% guidance. Healthcare Business Area at +16.0% YOY and Consumer & Industrial Business A
Slide 19: 2021 Results
2021 Results Delivered on guidance CHF millions Key figures Highlights 2021 2020 YOY adj.1 org.2 • Revenue back to pre-pandemic 2019 levels 2 Revenue 457.3 351.3 30.2% 30.2% 21.5% • Business area gross profit margin up 2.0 pts, Business Area Gross Profit 220.4 162.4 35.7% as margin mix benefits from
Slide 20: Outlook
Outlook medmix CONFIDENTIAL
Slide 21: Outlook
Outlook FY2022 • Targeting 8-10%1 growth in revenue adjusted for sanctions impact, and around 22% Adjusted EBITDA margin Mid-term • Medium-term aspiration is a compound annual growth rate (CAGR) of 8%1 in revenue and an adjusted EBITDA margin of 30% 1. FX adjusted 21 medmix CONFIDENTIAL
Slide 22: Your Investor Relations contact
Your Investor Relations contact Sheel Gill Head M&A, Strategy and IR Phone: +41 41 723 73 57 Mobile: +41 79 346 4172 Email: sheel.gill@medmix.com medmix Group AG Neuhofstrasse 20 6340 Baar Switzerland medmix CONFIDENTIAL